Leveraging Foundation Models and In Silico Perturbation to Accelerate Target Identification in Early Discovery

June 03, 2026
AI in Drug Discovery Stage
  • How in silico perturbation (ISP) can be used with single-cell foundation models to prioritize driver and rescue genes for target identification in early discovery 
  • A biologically grounded evaluation of ISP fidelity using embedding-based metrics: cell-state separation, directional shift toward target, baseline testing, and gene recovery ranking 
  • What we learn from benchmarking zero-shot models against a task-specific perturbation model and why simple baselines still matter 
  • How fine-tuning, model scale, and domain-matched pretraining change ISP performance, with practical guidance for model selection in different biological contexts 
Speakers
Xiong Liu
Xiong Liu, Director, Data Science and AI, Biomedical Research - Novartis